Nat Nasomyont, MD, MS
- Associate Director, Endocrinology Fellowship Program
- Assistant Professor, UC Department of Pediatrics
- Board Certified
About
Biography
As a pediatric endocrinologist, I provide comprehensive care for children and adolescents with hormone disorders, including growth and puberty problems, thyroid diseases and diabetes. I also evaluate and treat metabolic bone diseases and osteoporosis in childhood and adolescents.
My philosophy is to provide compassionate and personalized care. I like to engage children and their parents in developing the best treatment plan for them. I am board certified by the American Board of Pediatrics (2017) and Pediatric Endocrinology (2021). As a Certified Clinical Densitometrist (2020), I also provide service in bone density analysis as part of a comprehensive bone health evaluation.
My current research focuses on bone health in children and adolescents with conditions that may predispose them to a compromised peak bone mass. Childhood and adolescence are critical periods for bone mass accrual. I hope my work on the early identification and intervention for children at risk for low bone mass will ultimately prevent osteoporosis during their adult years.
MD: Siriraj Hospital Faculty of Medicine, Bangkok, Thailand, 2011.
Residency: Pediatrics, University of South Alabama, Mobile, AL, 2017.
Fellowship: Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2020.
MS: Clinical and Translational Research, University of Cincinnati, Cincinnati, OH, 2020.
Certification: American Board of Pediatrics, 2017; Pediatric Endocrinology, 2021; Certified Clinical Densitometrist (CCD), 2020.
Interests
Pediatric endocrinology; metabolic bone disease; pediatric osteoporosis; diabetes
Services and Specialties
Endocrinology
Interests
Metabolic bone disease; pediatric osteoporosis
Research Areas
Endocrinology
Locations (3)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Determinants of Bone Mass Accrual in Transgender and Gender Diverse Youth Undergoing Pubertal Suppression Therapy. Journal of Clinical Densitometry. 2024; 27:101505.
Elevated bone turnover markers predict bone mineral density accrual in adolescents with 21-hydroxylase deficiency. Clinical Endocrinology. 2023; 99:462-469.
Bone Mineral Density and Dickkopf-1 in Adolescents with Non-Deletional Hemoglobin H Disease. Journal of Clinical Densitometry. 2023; 26:101379.
Successful Treatment of Hypoglycemia With Alpelisib in Pediatric Patients With PIK3CA-Related Overgrowth Spectrum. 2023; 1:luad027.
Changes in Bone Marrow Adipose Tissue in Transgender and Gender Non-Conforming Youth Undergoing Pubertal Suppression: A Pilot Study. Journal of Clinical Densitometry. 2022; 25:485-489.
Chapter 37 Osteoporosis in childhood and adolescence. Marcus and Feldman's Osteoporosis. : Elsevier; Elsevier; 2021.
Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy. Osteoporosis International. 2020; 31:2449-2459.
Intravenous bisphosphonate therapy in children with spinal muscular atrophy. Osteoporosis International. 2020; 31:995-1000.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2024 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey